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Abstract We report the systemic cytokine and chemokine
response in children with the 2009 pandemic influenza A
(H1N1) virus infection. In patients with pneumonia, the
serum levels of IFN-γ and IL-5 were significantly higher
than those in patients without pneumonia. This tendency
was also present for IL-6, IL-8, IL-10, IL-13, and MCP-1 in
patients with pneumonia. Among patients with pneumonia,
the levels of MCP-1 were significantly higher in the group
of patients with pneumonia with severe respiratory failure
than patients with mild pneumonia.
Introduction
In late March and early April 2009, an outbreak of the 2009
pandemic influenza A (H1N1) virus infection was detected
in Mexico, with subsequent cases observed in many
countries, including the United States [1]. It was reported
that the 2009 H1N1 virus was identified as the cause of
outbreaks of febrile respiratory infection ranging from self-
limited to severe illness, and there were severe cases that
developed respiratory failure [2]. Cytokine responses to
influenza virus infection have been shown to contribute to
the pathogenesis and severity of influenza virus infection,
particularly influenza-associated encephalopathy (H1N1,
H3N2) and respiratory failure (H5N1) [3–5]. However, the
cytokine response during the 2009 H1N1 virus infection is
poorly understood. Therefore, we evaluated the systemic
cytokine and chemokine response during the 2009 H1N1
virus infection and studied the expression of cytokines and
chemokines in pediatric patients with pneumonia, one of the
major complications of the disease.
Methods
Thirty-four children with the 2009 H1N1 virus infection
who were admitted to our center between July and
December 2009 were included in this study. There were
25 boys and 9 girls, and their ages ranged from 2 to
11 years, with a median age of 6 years. 2009 H1N1 virus
infection was confirmed by the detection of the viral
genomes with the real time reverse transcription polymer-
ase chain reaction (RT-PCR) assay targeted at a region of
swine H1 HA gene using a nasal swab specimen obtained
at the time of admission. Twenty-one children with the
2009 H1N1 virus infection had pneumonia with abnormal
respiratory signs (weakness of breath sound, wheezing, and
hypoxia) and definite consolidation shadows or atelectasis
in their chest X-ray examinations, while another 13 patients
presented without pneumonia, including vomiting [6],
delirium [4], convulsion [1], liver dysfunction [1], and
pancytopenia [1]. Among 21 patients with pneumonia, 10
patients had severe pneumonia with respiratory failure; all
patients were admitted to an intensive care unit (ICU) and 5
of the 10 patients required mechanical ventilation. Seven
of the 10 patients with severe pneumonia had lobar or
multilobar atelectasis with consolidation shadow in their
chest x-ray examination. Another 11 patients with pneu-
monia had mild respiratory disorder, and none of them
had an ICU admission or underwent mechanical ventilation.
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serum obtained at the time of admission, which was within
the first 4 days after symptoms onset, were measured. We
assayed 17 cytokines in serum (IL-1β, IL-2, IL-4, IL-5, IL-
6, IL-7, IL-8, IL-10, IL-12, IL-13, IL-17, G-CSF, GM-CSF,
IFN-γ, MCP-1, MIP-1β, and TNF-α) by the Bio-Plex
suspension array system and the 17-Plex Panel (Bio-Rad
Laboratories, Tokyo, Japan). The Mann–Whitney U-test
was used for the statistical comparison of the two groups of
patients. p-values less than 0.01 were considered to be
significant in this study. The Institutional Review Board of
our center approved the protocols of the study. Written
Table 1 Patient characteristics
Patients with pneumonia (n=21) Patients without pneumonia (n=13)
Age (years) 8 (2–11) 6 (2–10)
Male sex (no.) 15 10
Illness day on admission (day) 2 (1–4) 2 (1–3)
Underlying medical conditions Asthma (no.) 7 1
Seizure disorder (no.) 1 2
Neurological disorders (no.) 0 1
Renal disease (no.) 1 0
Heart disease (no.) 0 1
Obesity (no.) 0 1
Clinical signs and symptoms Fever (no.) 21 13
Cough (no.) 21 9
Vomiting (no.) 0 6
Delirium (no.) 1 4
Convulsion (no.) 0 1
Liver dysfunction (no.) 0 1
Pancytopenia (no.) 0 1
Respiratory complications RR (/min) 40 (24–65) 28 (27–40)
SpO2 (%) 89 (82–96) 97 (95–99)
Weakness of breath sound (no.) 10 0
Wheezing (no.) 6 0
Hypoxia (no.) 21 0
Bacterial pneumonia (no.) 2 0
Chest X-ray Consolidation: unilateral (no.) 15/21 0/5
bilateral (no.) 4/21
Atelectasis (no.) 8/21 0/5
Outcome Oxygen requirement (no.) 21 0
ICU admission (no.) 10 0
Use of mechanical ventilation (no.) 5 0
Death 0 0
Duration of hospitalization (day) 6 (4–12) 5 (2–6)
Laboratory results WBC (×10
3/μl) 9.7 (1.8–23.6) 6.9 (2.6–10.3)
Ht (%) 37.8 (35.6–44.2) 36.3 (33.2–41.8)
Plt (×10
4/μl) 22.2 (13.0–70.3) 20.8 (8.5–30.1)
CRP (mg/dl) 2.8 (0.3–8.6) 0.7 (0.1–2.7)
AST (U/l) 29 (15–48) 35 (26–485)
ALT(U/l) 13 (4–53) 14(9–267)
LD(U/l) 294 (220–402) 318 (231–714)
CK (U/l) 125(9–248) 87 (43–896)
Data are given as medians (range)
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Results
Among the patients who presented with the 2009 H1N1
virus infection, there were no differences in the age, sex, or
illness day on admission between patients with pneumonia
and those without pneumonia (Table 1). The patients with
pneumonia were more likely to have asthma as an
underlying medical condition, oxygen administration, ICU
admission, and mechanical ventilation than patients without
pneumonia. Two patients with pneumonia showing leukocy-
tosis and elevated C-reactive protein (CRP) were suspected
to have a bacterial coinfection, but cultures of sputum or
nasopharyngeal swabs were not done.
Among measured cytokines and chemokines in the
children during the 2009 H1N1 virus infection, the serum
levels of IFN-γ and IL-5 in patients with pneumonia were
significantly higher than those in patients without pneumonia.
This tendency was also present for the serum levels of IL-6,
IL-8, IL-10, IL-13, and MCP-1 in patients with pneumonia
(Table 2).
The serum levels of IL-1β, IL-2, IL-4, and MCP-1 were
significantly higher in the group of patients with severe
pneumonia than in those with mild pneumonia (Table 3).
This tendency was also present for IL-5, IL-13, and TNF-α,
although it was not observed with the levels of IL-6, IFN-γ,
and other chemokines, such as IL-8 and MIP-1β.
Discussion
This study shows that the serum levels of IFN-γ , IL-5,
IL-6, IL-8, IL-10, IL-13, and MCP-1 in patients with
pneumonia were higher than that in patients without
pneumonia during the 2009 H1N1 virus infection. The levels
of IL-1β, IL-2, IL-4, and MCP-1 were significantly different
between patients with severe pneumonia and those with mild
pneumonia. Of note, MCP-1 was especially higher in patients
with severe pneumonia who developed respiratory failure.
These findings suggest that MCP-1 might contribute to the
pathogenesis and severity of respiratory complications in
the 2009 H1N1 virus infection or the degree of MCP-1
production could reflect the severity of the infection. In this
regard, it is intriguing that the MCP-1 knockout mice had a
reduced antiviral clearance, together with reduced leukocytes
recruitment into the lungs during infection with influenza A
[6]. In patients with severe pneumonia caused by influenza
Table 2 Level of cytokines and chemokines in the serum. Comparison
between patients with pneumonia and those without pneumonia
Patients with
pneumonia (n=21)
Patients without
pneumonia (n=13)
p-value
IL-1β −0.2 (und.–1.4) −0.9 (und.–2.6) 0.392
IL-2 1.0 (und.–2.3) 0.4 (und.–1.8) 0.150
IL-4 −0.1 (und.–0.7) und. (und.–0.8) 0.159
IL-5 1.0 (und.–2.5) und. (und.–0.8) <0.001
IL-6 1.8 (und.–3.4) 0.7 (−0.4–2.5) 0.035
IL-7 0.1 (und.–1.5) 0.3 (und.–1.7) 0.394
IL-8 1.1 (0.1–1.7) 0.5 (−0.6–1.7) 0.021
IL-10 1.2 (und.–2.3) und. (und.–2.1) 0.023
IL-12 −0.3 (und.–2.2) und. (und.–1.4) 0.176
IL-13 −0.2 (und.–1.4) und. (und.–0.5) 0.020
IL-17 und. (und.–1.9) und. 0.590
G-CSF 1.3 (und.–2.4) 0.7 (und.–2.1) 0.068
GM-CSF 1.3 (und.–2.7) 0.3 (und.–2.4) 0.282
IFN-γ 2.2 (und.–3.8) 1.5 (und.–3.2) 0.009
MCP-1 2.1 (und.–3.2) 1.4 (und.–2.5) 0.035
MIP-1β 1.7 (0.1–2.5) 1.1 (0–2.7) 0.074
TNF-α 1.4 (und.–2.4) und. (und.–2.2) 0.109
Data are given as median log10 pg per ml (range)
und., undetectable
Table 3 Level of cytokines and chemokines in the serum. Comparison
between patients with severepneumonia and those with mild pneumonia
Pneumonia p-value
Severe (n=10) Mild (n=11)
IL-1β und. (und.–1.4) und. (und.–0.7) 0.005
IL-2 1.4 (−0.2–2.3) 0.8 (und.–1.5) 0.009
IL-4 0.5 (und.–0.7) und. (und.–0.6) 0.008
IL-5 1.6 (−1.2–2.5) 0 (und.–2.4) 0.024
IL-6 2.1 (0.4–3.4) 1.5 (und.–2.4) 0.078
IL-7 0.2 (und.–1.5) −0.1 (und.–1.5) 0.698
IL-8 1.1 (0.2–1.6) 1.1 (0.1–1.7) 0.725
IL-10 1.4 (und.–2.3) 0.4 (und.–1.7) 0.075
IL-12 0.9 (und.–2.2) und. (und.–1.1) 0.060
IL-13 0.9 (und.–1.4) −1.0 (und.–1.0) 0.027
IL-17 und. (und.–1.9) und. 0.056
G-CSF 1.5 (und.–2.4) 1.1 (und.–2.2) 0.379
GM-CSF 1.6 (und.–2.7) 0.5 (und.–1.9) 0.056
IFN-γ 2.5 (und.–3.8) 1.9 (und.–3.3) 0.091
MCP-1 2.5 (1.0–3.2) 1.5 (und.–2.4) 0.007
MIP-1β 1.8 (0.5–2.5) 1.5 (0.1–2.5) 0.105
TNF-α 2.5 (und.–2.4) −0.1 (und.–2.0) 0.038
Data are given as median log10 pg per ml (range)
und., undetectable
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as IP-10, MIG, MCP-1, and IL-8, in the peripheral blood
were elevated and particularly high in those with fatal
outcome [5]. Experimental data in a human lung organ
culture model showed that influenza viruses (H1N1 and
H3N2) proliferated in the bronchial epithelial cells and
induced the production of MCP-1, MIP-1, IL-8, and IP-10
[7]. On the other hand, in pigs infected by the 2009 H1N1
virus, the levels of IL-6, IFN-α,a n dT N F - α in the broncho-
alveolar lavage fluid were elevated, but the concentrations of
chemokines were not measured [8] and the roles of chemo-
kines in respiratory complications of the 2009 H1N1 virus
infection remains to be investigated. We speculate that the
2009 H1N1 virus proliferates in the bronchial epithelial cells
in patients and induces the production of several chemo-
kines, which cause the inflammation of the airway, followed
by severe respiratory complications.
Influenza-associated encephalopathy is a severe neuro-
logic complication of influenza virus infection [9]. Although
the pathogenesis of this complication is still unclear, the
serum levels of proinflammatory cytokines, including IL-1β,
IL-6, and TNF-α, have been shown to be elevated and
related to the clinical severity of [3, 4]. Among patients with
this type of encephalopathy, the serum TNF-α values at
onset were significantly higher in patients who died
compared to those who survived [3, 4]. The present study
shows a characteristic cytokine profile in the patients with
pneumonia during the 2009 H1N1 virus infection which is
different from what is observed in influenza-associated
encephalopathy. The secretion of cytokines and chemokines
during the acute phase of the 2009 H1N1 virus infection
were clearly different depending on the presenting symp-
toms. This suggests that an early-phase response of
cytokines and chemokines during the 2009 H1N1 virus
infection might have contributed to the pathogenesis of the
disease. In conclusion, the present study shows that the
production of several chemokines, especially MCP-1, may
have a role in the pathogenesis of respiratory complications
during the 2009 H1N1 virus infection.
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